Vertex Pharmaceuticals Inc (VRTX) 126.94 $VRTX
Post# of 64070
Posted On: 03/16/2015 2:30:15 PM
Vertex Pharmaceuticals Inc (VRTX) 126.94 $VRTX
PDUFA date approaches for Kalydeco label expansion
Seeking Alpha - at Seeking Alpha - 1 hr 36 mins ago
VRTX: 126.94 (+2.94)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 14.90 (+0.13), VRTX: 126.94 (+2.94), CERU: 8.08 (+0.06), FOMX: 10.29 (+0.09), ONTX: 2.24 (-0.01), PFNX: 13.93 (-0.26), OMER: 23.99 (-1.22), PGNX: 6.58 (-0.51), SYN: 2.66 (-0.23), VCYT: 7.65 (-0.03), STEM: 1.17 (-0.07), APRI: 1.92 (-0.15), KPTI: 30.35 (+2.27)
Concert Pharma initiates Phase 1 study of deuterium-modified cystic fibrosis drug
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 7:09AM CDT
VRTX: 126.94 (+2.94), CNCE: 16.61 (+0.99)
After Yesterday's Decline of 1.21%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Mar 11, 4:11PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $121.78 to a high of $124.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $123.90 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 126.94 (+2.94)
Vertex Pharmaceuticals Falls 1.21% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Mar 11, 4:11PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $121.78 to a high of $124.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $123.90 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 126.94 (+2.94)
Biotech Stock Roundup: AbbVie to Buy Pharmacyclics, FDA Approves First Biosimilar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 11, 8:54AM CDT
Mergers and acquisitions show no sign of slowing down with AbbVie (ABBV) announcing that it will acquire Pharmacyclics(PCYC) for $21 billion.
VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), GILD: 101.24 (+1.63), UTHR: 174.16 (+10.86), AMGN: 161.92 (+7.66), ABBV: 58.84 (+0.84), REGN: 447.67 (+18.29)
3 Biotech Stocks to Buy in March
Brian Orelli, Dan Caplinger, and Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 11, 7:04AM CDT
"Our life is March weather, savage and serene in one hour." -- Ralph Waldo Emerson Substitute "biotechs" for "our life" and you have the investing version of Emerson's quote. Depending on how binary events go, they can certainly become savage...
VRTX: 126.94 (+2.94), ICPT: 296.33 (+14.95), CUR: 2.39 (-0.17)
Hemispherx Uses Ebola Tragedy to Raise Cash, Pay Executive Bonuses
at The Street - Tue Mar 10, 10:10AM CDT
Since the end of September, Hemispherx sold almost 25 million shares of company stock, equivalent to the amount of stock sold in the first nine months of 2014.
VRTX: 126.94 (+2.94), SGEN: 39.07 (+0.76), HEB: 0.23 (unch)
Senior Housing Properties Trust: Price Appreciation Needs To Improve For This 7% Yielder
David Zanoni - at Seeking Alpha - Sun Mar 08, 12:15AM CST
VRTX: 126.94 (+2.94), SNH: 21.73 (+0.19)
Stocks Open Quietly Higher; Drugmakers Rally On AbbVie Deal
at Investor's Business Daily - Thu Mar 05, 9:44AM CST
Stocks opened higher in soft trade Thursday, helped by drugmakers moving higher on the heels of a $21 billion acquisition. The Nasdaq paced the market with a 0.5% gain. The Dow Jones industrial average gained 0.3%. The S&P 500 added 0.2%. The stock...
MNK: 126.09 (+1.97), VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), KR: 76.96 (+0.61), MYL: 60.84 (+1.08), COST: 149.75 (+0.47), ABBV: 58.84 (+0.84)
Today's Unusual Social Activity Stock: Vertex Pharmaceuticals (VRTX)
at The Street - Thu Mar 05, 8:53AM CST
Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as an unusual social activity candidate
VRTX: 126.94 (+2.94)
AbbVie's high-priced takeout of Pharmacyclics bodes well for other biotechs with high potential drugs
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 7:52AM CST
VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), BMRN: 124.33 (+0.81), UTHR: 174.16 (+10.86), AMGN: 161.92 (+7.66), DYAX: 17.62 (+0.32), JNJ: 100.72 (+1.51), ESPR: 76.71 (+2.32), KITE: 62.70 (-0.39), RCPT: 149.38 (-0.04), PTCT: 73.28 (+0.01), ICPT: 296.33 (+14.95), ABBV: 58.84 (+0.84), JUNO: 52.11 (+2.62), SNY: 48.56 (+1.49)
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 04, 10:35AM CST
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.
OREX: 6.98 (-0.06), VRTX: 126.94 (+2.94), ISIS: 72.00 (+1.34), GILD: 101.24 (+1.63), AMGN: 161.92 (+7.66), ARNA: 4.76 (-0.05), CELG: 120.40 (+2.67)
BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District
PR Newswire - Mon Mar 02, 5:30AM CST
BioMed Realty Trust, Inc. (NYSE: BMR) today announced it has recaptured approximately 313,000 square feet of space in the most dynamic and valuable life science real estate market in the world through the termination of Vertex Pharmaceuticals' leases on three properties in Cambridge, Massachusetts effective February 28, 2015. BioMed Realty will receive a $14 million termination fee from Vertex and will immediately begin to reposition the properties to meet the growing demand for lab space from new life science companies in this core innovation district.
BMR: 21.76 (+0.17), VRTX: 126.94 (+2.94)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Feb 26, 10:07AM CST
Is Pharmacyclics (PCYC) up for sale? J&J and Novartis are rumored to be interested in acquiring the company.
VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), VVUS: 3.01 (+0.19), AMGN: 161.92 (+7.66), ALKS: 66.80 (+0.41), REGN: 447.67 (+18.29), CELG: 120.40 (+2.67)
PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer
at The Street - Wed Feb 25, 10:47AM CST
To buy PTC Therapeutics today would cost roughly $3 billion, a significant pile of cash to risk on an investment that could blow up at the end of the year.
VRTX: 126.94 (+2.94), BMRN: 124.33 (+0.81), SHPG: 244.61 (+0.43), PTCT: 73.28 (+0.01)
What to Expect From Vertex Pharma's Next Cystic Fibrosis Drug Results
at The Street - Mon Feb 23, 10:06AM CST
Later this quarter, Vertex Pharmaceuticals will be disclosing new clinical data on its next cystic fibrosis drug, VX-661. Here's a preview.
VRTX: 126.94 (+2.94)
Surprise! We Still Need Drugmakers to Develop Revolutionary Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 17, 10:02AM CST
Source: Gilead Sciences. All of the market's chatter surrounding Gilead Sciences ' and AbbVie 's hepatitis C drugs this past year may have you thinking that these companies have won the decades long battle against this tough-to-treat disease....
VRTX: 126.94 (+2.94), GILD: 101.24 (+1.63), CVS: 104.14 (+0.88), ABBV: 58.84 (+0.84)
3 Upcoming FDA Decisions We're Most Excited About
Motley Fool Staff - Motley Fool - Mon Feb 16, 7:08AM CST
Biotech stocks can often make big moves after reporting trial data, but it's FDA drug approvals or denials that can really make stocks in the industry pop or drop. For that reason, we asked three Motley Fool experts what FDA decisions they're most...
VRTX: 126.94 (+2.94), REGN: 447.67 (+18.29), CELG: 120.40 (+2.67)
Could This Be The Biggest Advance in Hepatitis C since Gilead Sciences' Sovaldi?
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 16, 6:41AM CST
Tiny biotech stock Achillion Pharmaceuticals reported what could be pretty big news for hepatitis C patients this week. The clinical stage biotechnology company released data showing that combining its ACH-3102 with Gilead Sciences ' Sovaldi...
VRTX: 126.94 (+2.94), GILD: 101.24 (+1.63), ACHN: 11.25 (-0.05), MRK: 57.08 (+0.88)
PDUFA date approaches for Kalydeco label expansion
Seeking Alpha - at Seeking Alpha - 1 hr 36 mins ago
VRTX: 126.94 (+2.94)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 14.90 (+0.13), VRTX: 126.94 (+2.94), CERU: 8.08 (+0.06), FOMX: 10.29 (+0.09), ONTX: 2.24 (-0.01), PFNX: 13.93 (-0.26), OMER: 23.99 (-1.22), PGNX: 6.58 (-0.51), SYN: 2.66 (-0.23), VCYT: 7.65 (-0.03), STEM: 1.17 (-0.07), APRI: 1.92 (-0.15), KPTI: 30.35 (+2.27)
Concert Pharma initiates Phase 1 study of deuterium-modified cystic fibrosis drug
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 7:09AM CDT
VRTX: 126.94 (+2.94), CNCE: 16.61 (+0.99)
After Yesterday's Decline of 1.21%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Mar 11, 4:11PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $121.78 to a high of $124.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $123.90 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 126.94 (+2.94)
Vertex Pharmaceuticals Falls 1.21% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Mar 11, 4:11PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $121.78 to a high of $124.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $123.90 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 126.94 (+2.94)
Biotech Stock Roundup: AbbVie to Buy Pharmacyclics, FDA Approves First Biosimilar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 11, 8:54AM CDT
Mergers and acquisitions show no sign of slowing down with AbbVie (ABBV) announcing that it will acquire Pharmacyclics(PCYC) for $21 billion.
VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), GILD: 101.24 (+1.63), UTHR: 174.16 (+10.86), AMGN: 161.92 (+7.66), ABBV: 58.84 (+0.84), REGN: 447.67 (+18.29)
3 Biotech Stocks to Buy in March
Brian Orelli, Dan Caplinger, and Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 11, 7:04AM CDT
"Our life is March weather, savage and serene in one hour." -- Ralph Waldo Emerson Substitute "biotechs" for "our life" and you have the investing version of Emerson's quote. Depending on how binary events go, they can certainly become savage...
VRTX: 126.94 (+2.94), ICPT: 296.33 (+14.95), CUR: 2.39 (-0.17)
Hemispherx Uses Ebola Tragedy to Raise Cash, Pay Executive Bonuses
at The Street - Tue Mar 10, 10:10AM CDT
Since the end of September, Hemispherx sold almost 25 million shares of company stock, equivalent to the amount of stock sold in the first nine months of 2014.
VRTX: 126.94 (+2.94), SGEN: 39.07 (+0.76), HEB: 0.23 (unch)
Senior Housing Properties Trust: Price Appreciation Needs To Improve For This 7% Yielder
David Zanoni - at Seeking Alpha - Sun Mar 08, 12:15AM CST
VRTX: 126.94 (+2.94), SNH: 21.73 (+0.19)
Stocks Open Quietly Higher; Drugmakers Rally On AbbVie Deal
at Investor's Business Daily - Thu Mar 05, 9:44AM CST
Stocks opened higher in soft trade Thursday, helped by drugmakers moving higher on the heels of a $21 billion acquisition. The Nasdaq paced the market with a 0.5% gain. The Dow Jones industrial average gained 0.3%. The S&P 500 added 0.2%. The stock...
MNK: 126.09 (+1.97), VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), KR: 76.96 (+0.61), MYL: 60.84 (+1.08), COST: 149.75 (+0.47), ABBV: 58.84 (+0.84)
Today's Unusual Social Activity Stock: Vertex Pharmaceuticals (VRTX)
at The Street - Thu Mar 05, 8:53AM CST
Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as an unusual social activity candidate
VRTX: 126.94 (+2.94)
AbbVie's high-priced takeout of Pharmacyclics bodes well for other biotechs with high potential drugs
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 7:52AM CST
VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), BMRN: 124.33 (+0.81), UTHR: 174.16 (+10.86), AMGN: 161.92 (+7.66), DYAX: 17.62 (+0.32), JNJ: 100.72 (+1.51), ESPR: 76.71 (+2.32), KITE: 62.70 (-0.39), RCPT: 149.38 (-0.04), PTCT: 73.28 (+0.01), ICPT: 296.33 (+14.95), ABBV: 58.84 (+0.84), JUNO: 52.11 (+2.62), SNY: 48.56 (+1.49)
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 04, 10:35AM CST
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.
OREX: 6.98 (-0.06), VRTX: 126.94 (+2.94), ISIS: 72.00 (+1.34), GILD: 101.24 (+1.63), AMGN: 161.92 (+7.66), ARNA: 4.76 (-0.05), CELG: 120.40 (+2.67)
BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District
PR Newswire - Mon Mar 02, 5:30AM CST
BioMed Realty Trust, Inc. (NYSE: BMR) today announced it has recaptured approximately 313,000 square feet of space in the most dynamic and valuable life science real estate market in the world through the termination of Vertex Pharmaceuticals' leases on three properties in Cambridge, Massachusetts effective February 28, 2015. BioMed Realty will receive a $14 million termination fee from Vertex and will immediately begin to reposition the properties to meet the growing demand for lab space from new life science companies in this core innovation district.
BMR: 21.76 (+0.17), VRTX: 126.94 (+2.94)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Feb 26, 10:07AM CST
Is Pharmacyclics (PCYC) up for sale? J&J and Novartis are rumored to be interested in acquiring the company.
VRTX: 126.94 (+2.94), PCYC: 256.06 (+1.08), VVUS: 3.01 (+0.19), AMGN: 161.92 (+7.66), ALKS: 66.80 (+0.41), REGN: 447.67 (+18.29), CELG: 120.40 (+2.67)
PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer
at The Street - Wed Feb 25, 10:47AM CST
To buy PTC Therapeutics today would cost roughly $3 billion, a significant pile of cash to risk on an investment that could blow up at the end of the year.
VRTX: 126.94 (+2.94), BMRN: 124.33 (+0.81), SHPG: 244.61 (+0.43), PTCT: 73.28 (+0.01)
What to Expect From Vertex Pharma's Next Cystic Fibrosis Drug Results
at The Street - Mon Feb 23, 10:06AM CST
Later this quarter, Vertex Pharmaceuticals will be disclosing new clinical data on its next cystic fibrosis drug, VX-661. Here's a preview.
VRTX: 126.94 (+2.94)
Surprise! We Still Need Drugmakers to Develop Revolutionary Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 17, 10:02AM CST
Source: Gilead Sciences. All of the market's chatter surrounding Gilead Sciences ' and AbbVie 's hepatitis C drugs this past year may have you thinking that these companies have won the decades long battle against this tough-to-treat disease....
VRTX: 126.94 (+2.94), GILD: 101.24 (+1.63), CVS: 104.14 (+0.88), ABBV: 58.84 (+0.84)
3 Upcoming FDA Decisions We're Most Excited About
Motley Fool Staff - Motley Fool - Mon Feb 16, 7:08AM CST
Biotech stocks can often make big moves after reporting trial data, but it's FDA drug approvals or denials that can really make stocks in the industry pop or drop. For that reason, we asked three Motley Fool experts what FDA decisions they're most...
VRTX: 126.94 (+2.94), REGN: 447.67 (+18.29), CELG: 120.40 (+2.67)
Could This Be The Biggest Advance in Hepatitis C since Gilead Sciences' Sovaldi?
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 16, 6:41AM CST
Tiny biotech stock Achillion Pharmaceuticals reported what could be pretty big news for hepatitis C patients this week. The clinical stage biotechnology company released data showing that combining its ACH-3102 with Gilead Sciences ' Sovaldi...
VRTX: 126.94 (+2.94), GILD: 101.24 (+1.63), ACHN: 11.25 (-0.05), MRK: 57.08 (+0.88)
(0)
(0)Scroll down for more posts ▼